EVOLITO
22.9.2021 13:17:13 CEST | Business Wire | Press release
Evolito, a new company developing and manufacturing electric motors and power electronics for aerospace applications, launched publicly today as a privately-owned business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005519/en/
Evolito was spun out earlier this year by YASA (the world-leading pioneer of automotive axial-flux electric motors acquired by Mercedes-Benz in July 2021) to exclusively commercialise YASA’s next-generation electric motor technology and IP for the rapidly-growing aerospace market.
The business’s axial-flux motor technology has been proven in volume series production in the automotive industry and has even greater advantages in the aerospace market. As such, Evolito is uniquely positioned to drive forward the commercialisation and adoption of electric flight.
Evolito’s ultra high-performance, low-weight axial-flux motors and power electronics are smaller, lighter and more robust than any other competing technology, opening up a range of new opportunities for Electric Vertical Take-off and Landing (eVTOL), Fixed Wing and distributed electric propulsion applications such as Urban Air Mobility (UAM).
The unique segmented topology of the Evolito motor is inherently more robust than other electric motor approaches, making it ideally suited to the demands of the aerospace market where safety is paramount.
Cyrus Jilla, Partner and Board Director, Waypoint Capital said, “At Waypoint, one of our thematic interests is in energy transition and sustainability, including electrification. We look to invest in businesses with unique disruptive technology led by outstanding teams. Evolito is a perfect fit for us and we look forward to backing the team as they develop their game-changing electrification solutions for the aerospace market, making emissions-free flight a reality.”
Alexis Zervoglos, Senior Partner, OSE said, “The electrification of flight is one of the most exciting market opportunities of our time. Realising this potential will require innovative new technology and an ability to scale to meet the fast-emerging demand. OSE is delighted to be supporting Evolito on its mission to accelerate the adoption of electric flight.”
Gareth Morris, Managing Director, Evolito said, “Electrification in aerospace is some ten years behind that of the automotive industry, but the market potential is huge. Electric Vertical Take-off and Landing, Electric Helicopter, Fixed-Wing and Urban Air Mobility aircraft need high power density, low weight electric powertrains with inherently high safety factors - a combination of attributes that are unique to our axial-flux electric motor and power electronics. By leveraging YASA’s unique IP in the aerospace market, Evolito will fast-track the commercialisation of electric flight and transform mobility as we know it.”
EDITOR’S NOTES
Electric drive solutions for the Urban Air Mobility market are forecast to grow to USD $90 billion and 160,000 vehicles by 2050. Source: Roland Berger “The high-flying industry: Urban Air Mobility takes off” , Nov, 2020.
Evolito http://www.evolito.co.uk/
Evolito is making all-electric flight a commercial reality with world-leading direct-drive electric propulsion solutions. Spun out of YASA in 2021, Evolito leverages technology proven by OEMs in the EV industry. Evolito’s axial-flux electric motors and power electronics offer the highest power and torque densities in class – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications – and is inherently more robust than competing technologies. The privately-held company is based in Oxford. Evolito’s investors include Waypoint Capital and Oxford Science Enterprises (OSE).
YASA http://www.yasa.com/
YASA, part of Mercedes-Benz AG, is a pioneer in next-generation electric drive technology. YASA’s unique axial-flux electric motor technology offers the greatest efficiencies and highest power densities in class for the smallest size and weight. YASA is based in Oxford and Welshpool, UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005519/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom